ClinicalTrials.gg
Not yet recruitingNCT06223113Updated Feb 1, 2024

Evaluation of Safety and Performance of the EyenableTM Intraocular Lens for Cataract Treatment

An interventional study of EyenableTM PA60AS1 IOL in Cataract, sponsored by Xi'an Eyedeal Medical Technology Co., Ltd. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-01.

Sponsored by Xi'an Eyedeal Medical Technology Co., Ltd · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2025, 1 year 9 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Cataract is characterized by the loss of the normal transparency of the crystalline lens. It is a progressive, chronic disease that affect individuals over the age of 50. It is the leading cause of blindness around the world. The EyenableTM IOL (PA60AS1) is a CE-marked foldable single-piece ultra-violet absorbing posterior chamber intraocular lens (IOL). It is an optical implant to replace the human crystalline lens in the visual correction of aphakia in adult patients after cataract removal. This post-market clinical study will investigate the implantation safety and performance of the EyenableTM PA60AS1 intraocular lens (IOL) up to 6 month after the surgery.

02

Conditions studied

  • Cataract

Browse trials for

Keywords

  • Intraocular lens
03

In context

Cataract

1,633 studies on the registry are indexed under Cataract; 234 are open to participants now.

This study's planned enrollment of 200 is above the median of 79 across 1,094 interventional studies indexed under Cataract.

Browse Cataract studies →

Lead sponsor

Xi'an Eyedeal Medical Technology Co., Ltd is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults (≥ 18 years of age at the time of surgery) of any gender, diagnosed with age related cataracts in one or both eyes.
  2. Opacity of crystalline lens due to cataract and reduced vision assessed by patient complaints.
  3. Calculated lens power within the available range for the EyenableTM PA60AS1 IOL (+10D to +30.00D)
  4. Planned cataract removal by phacoemulsification procedure
  5. Clear intraocular media other than cataract, in the study eye
  6. Pharmacologically dilated pupil size of at least 6.0mm.
  7. 2.0 D or less of preoperative astigmatism in the study eye
  8. Willing and able to complete all required postoperative visits
  9. Able and willing to comprehend and sign or through a representative, with a witness present, an EC approved Form (ICF).

Exclusion criteria

Exclusion Criteria:

  1. Subject who, in the judgment of the clinical investigator, is not suitable for participation in the study for any clinical reason, as documented by the investigator on the patient's Case Report Forms (CRFs).
  2. Any type of cataract other than age-related.
  3. History of any intraocular, retinal, corneal or refractive surgery in the study eye (including LASIK, PRK, SMILE, etc.), only in the opinion of investigator that it could confound study outcome
  4. Ocular conditions which could affect the stability of the IOL (e.g., pseudoexfoliation, zonular dialysis, evident zonular weakness or dehiscence, etc.) in the study eye.
  5. Any anterior segment pathology likely to increase the risk of complications from phacoemulsification cataract extraction (e.g., chronic uveitis, iritis, iridocyclitis, aniridia, rubeosis iridis, corneal disorders, (Fuchs', or anterior basement membrane dystrophy, etc.) in the study eye.
  6. Mature cataract that is likely to prolong phacoemulsification and/or lead to intraoperative complications prior to attempted IOL implantation.
  7. Any visually significant intraocular media opacity other than cataract in the study eye.
  8. History of any clinically significant retinal pathology or ocular diagnosis (e.g., diabetic retinopathy, ischemic disease, macular degeneration, retinal detachment, amblyopia, optic neuropathy, microphthalmos, aniridia, neuro-ophthalmic disease, fixation problems etc.) in the study eye that could alter or limit final postoperative visual prognosis.
  9. History of cystoid macular edema in the study eye.
  10. Severe dry eye that, in the opinion of the investigator, would impair the ability to obtain reliable study measurements.
  11. Uncontrolled glaucoma and/or optic atrophy in the study eye.
  12. Extremely shallow anterior chamber (\< 2.0 mm).
  13. Irregular astigmatism, corneal degeneration or dystrophy.
  14. Uncontrolled systemic disease (e.g., diabetes mellitus, active cancer treatment, mental illness, etc.) in the opinion of the investigator, would put the subject's health at risk and/or prevent the subject from completing all study visits.
  15. Systemic medication that, in the opinion of the investigator, may confound the outcome or increase the intraoperative and post-operative risk to the subject (e.g., tamsulosin hydrochloride)
  16. Subjects who may reasonably be expected to require any additional ophthalmic surgical intervention at any time during the study (other than YAG capsulotomy).
  17. Need for concomitant procedures (e.g., glaucoma surgery, LRI, PRK, LASIK, etc.).
  18. Participation in any other drug or device clinical trial within 30 days prior to enrolling this study and/or during study participation.
  19. Pregnancy or lactation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Other
    EyenableTM PA60AS1 IOL implanation

    IOL implantation

    Device: EyenableTM PA60AS1 IOL

Interventions

  • DeviceEyenableTM PA60AS1 IOL

    Subjects will undergo surgery to remove cataract (the cloudy lenses) via phacoemulsification, and implant the Eyedeal® EyenableTM PA60AS1 IOL in the eye capsule.

06

What researchers measure

Primary outcomes

  1. SAFETY OUTCOME MEASURE - Adverse event

    The primary safety endpoints include rates of adverse events, loss of CDVA, slit lamp examination, fundus examination, intraocular pressure, device deficiencies.

    Time frame: 6 month after the device implantation.

  2. PERFORMANCE OUTCOME MEASURE - uncorrected distance visual acuity (UCDVA)

    Measurement of UCDVA

    Time frame: 6 month after the device implantation

  3. PERFORMANCE OUTCOME MEASURE - Corrected distance visual acuity (CDVA)

    Measurement of CDVA

    Time frame: 6 month after the device implantation

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2024; primary completion for Feb 2025, 12 months later.

Of 190 industry-sponsored interventional studies with no phase under Cataract, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 28. This study's planned 12 months is below that.

Counting every sponsor, half of 494 studies reached it within 17 months; a quarter within 9 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2024
First posted
Jan 25, 2024
StartEst.
Feb 2024
Primary completionEst.
Feb 2025
CompletionEst.
Feb 2025
Last update
Feb 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06223113
Lead sponsor
Xi'an Eyedeal Medical Technology Co., Ltd
Responsible party
Sponsor
First posted
Jan 25, 2024
Start date
Feb 2024 (estimated)
Primary completion
Feb 2025 (estimated)
Completion
Feb 2025 (estimated)
Last update
Feb 1, 2024

Study contacts

Q. Trin Peng, MD
Contact
info@eyedeal.com
+86 029 848 88888

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion